NCT01440387View on ClinicalTrials.gov

A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older

PHASE3CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

October 22, 2011

Study Completion Date

October 22, 2011

Conditions
Influenza
Interventions
BIOLOGICAL

FLULAVAL® QUADRIVALENT

Intramuscular injection, 1 dose each in FLULAVAL QUADRIVALENT Adults and FLULAVAL QUADRIVALENT Elderly Groups

Trial Locations (1)

J1H 1Z1

GSK Investigational Site, Sherbrooke

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01440387 - A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older | Biotech Hunter | Biotech Hunter